4/19/2013

The FDA has given orphan-drug status to Infinity Pharmaceuticals' IPI-145, an experimental drug for chronic lymphocytic leukemia and small lymphocytic lymphoma. The drug is in early-stage studies, and Infinity plans to begin at least two more trials this year.

Related Summaries